Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
NCT00038610
Completed
The goal of this clinical research study is to learn if intensive chemotherapy, combined with imatinib mesylate (Gleevec, STI571) given for 8 courses over 6 months, followed by maintenance imatinib mesylate plus chemotherapy for 2 years, followed by imatinib mesylate indefinitely can improve Philadelphia-positive acute lymphoblastic leukemia. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
08/19/2015
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00003605
Withdrawn
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy and monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab plus cyclophosphamide in treating patients who have indolent stage III or stage IV non-Ho... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/17/2015
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California +2 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
NCT00004039
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining interferon alfa or the monoclonal antibody rituximab with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy plus interferon alfa or rituximab in treating patients who have high risk stage III or stage IV lymphoma.
Gender:
ALL
Ages:
All
Trial Updated:
08/17/2015
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
NCT00559104
Completed
RATIONALE: Giving chemotherapy and radiation therapy to the entire body before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. The patient's stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying the side effects of giving combination chemotherapy together with or without total-body irradiat... Read More
Gender:
ALL
Ages:
Between 16 years and 59 years
Trial Updated:
07/17/2015
Locations: Good Samaritan Regional Medical Center, Phoenix, Arizona +1 locations
Conditions: Lymphoma
Register for Updates
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
NCT00003414
Completed
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells. Interleukin-2 and interferon gamma may enhance the effectiveness of graft-versus-host disease to kill cancer cells. PURPOSE: Randomized phase III trial to determine the effectiveness of graft-versus-host disease in treating patients who have recurrent or refractory lymphoma or Hodgkin's disease .
Gender:
ALL
Ages:
All
Trial Updated:
07/16/2015
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Graft Versus Host Disease, Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00004092
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of combination chemotherapy and comparing them to see how well they work in treating patients with high-risk primary stage II or stage III breast cancer.
Gender:
ALL
Ages:
60 years and below
Trial Updated:
07/07/2015
Locations: Banner Good Samaritan Medical Center, Phoenix, Arizona +1 locations
Conditions: Breast Cancer
Register for Updates
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
NCT02446431
Recruiting
Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, frequently have recurrent disease which is then treated with ad hoc regimens or early phase therapies with little benefit to the patient. Metronomic therapy (MC), defined as lower dose continuous drug exposure, has been successfully tested in pediatric leukemias with excellent results in terms of improved outcome, toxicity profiles, and cost.... Read More
Gender:
ALL
Ages:
Between 12 months and 31 years
Trial Updated:
05/13/2015
Locations: Miller Children's and Women's Hospital Long Beach, Long Beach, California +1 locations
Conditions: Solid Tumor
Register for Updates
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00072566
Completed
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as cyclo... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
05/08/2015
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
Register for Updates
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
NCT00022230
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving chemotherapy together with biological therapy and to see how well they work in treating patients with stage II or stage III breas... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/04/2015
Locations: Roger Williams Medical Center, Providence, Rhode Island
Conditions: Breast Cancer
Register for Updates
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
NCT00669890
Terminated
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated. This study will attempt to determine the maximum tolerated dose of the immune therapy (gemtuzumab) when given in combination with the myeloablative (high dose) drugs used in this study for allogeneic stem cell transplant. (Part A)
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/20/2015
Locations: Morgan Stanley Children's Hospital of NYP, New York City, New York
Conditions: Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Register for Updates
Effects of Exercise in Combination With Epoetin Alfa
NCT00577096
Completed
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training for patients being treated with high-dose chemotherapy and autologous peripheral bloodstem cell transplantation (PBSC T) for multiple myeloma. The endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of RBC an... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2015
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
NCT00958256
Completed
The goal of this clinical research study is to learn if bortezomib when given in combination with cyclophosphamide and rituximab can help to control mantle cell lymphoma. The safety of this drug combination will also continue to be studied.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/31/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma, Lymphoma
Register for Updates